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Background: Reports from Africa have suggested that pneumocystis pneumonia (PCP) is a less important cause of
morbidity than in the developed world. However, more recent studies have shown high seroprevalence rates of
P. jirovecii in healthy individuals with HIV as well as high rates of clinical disease in African children. This suggests
that PCP may be more common in Africa than was previously recognised. Understanding the contribution of
PCP to disease in HIV-infected individuals in sub-Saharan Africa (SSA) has important implications for diagnosis,
management and resource allocation. We therefore propose to conduct a systematic review and meta-analysis in
order to investigate the burden of PCP in this population.
Methods and design: We plan to search electronic databases and reference lists of relevant articles published from
1995 to May 2013 using broad terms for pneumocystis, HIV/AIDS and sub-Saharan Africa. Studies will be included if
they provide clear diagnostic criteria for PCP and well-defined study populations or mortality data (denominator).
A novel quality score assessment tool has been developed to ensure fidelity to inclusion criteria, minimise risk of
selection bias between reviewers and to assess quality of outcome ascertainment. This will be applied to eligible
full-text articles. We will extract data using a standardised form and perform descriptive and quantitative analysis to
assess PCP prevalence, mortality and case fatality, as well as the quality of included studies. This review protocol has
been published in the PROSPERO International Prospective Register of systematic reviews, registration number
CRD42013005530.
Discussion: Our planned review will contribute to the diagnosis and management of community-acquired
pneumonia in HIV-infected individuals in SSA by systematically assessing the burden of PCP in this population. We
also describe a novel quality assessment tool that may be applied to other prevalence reviews.Background
Pneumocystis pneumonia (PCP), once the most common
opportunistic infection in HIV in developed countries, has
declined significantly since the introduction of combi-
nation antiretroviral therapy and cotrimoxazole prophy-
laxis in those regions [1]. In contrast, early reports from
developing countries suggested that PCP was a less im-
portant cause of morbidity and mortality, and that other
AIDS-associated opportunistic infections such as tubercu-
losis and enteric pathogens predominate [2-7]. The appa-
rently low burden of PCP among African adults may be* Correspondence: Sean.wasserman@uct.ac.za
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article, unless otherwise stated.explained by early mortality from other more virulent in-
fections and limited access to sensitive diagnostic tests
[8,9]. This hypothesis is supported by a recent systematic
review demonstrating a linear relationship between PCP
diagnoses and rising gross domestic product in low- and
middle-income countries [10]. It has also been suggested
that environmental and virulence factors may account for
the differences in incidence in Africa [11].
However, more recent studies have revealed a high
seroprevalence of P. jirovecii, the cause of PCP, in heal-
thy individuals with HIV [12,13] as well as high rates of
clinical disease in African children [14-16]. The reported
increase in prevalence among adults in the 1990s, pos-
sibly as a result of better access to diagnostics and treat-
ment [17], may reflect the true epidemiology of PCP,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Wasserman et al. Systematic Reviews 2013, 2:112 Page 2 of 6
http://www.systematicreviewsjournal.com/content/2/1/112suggesting that this infection may be a more important
cause of community-acquired pneumonia in Africa than
was previously recognised.
The World Health Organization (WHO) recommends
that patients in resource-limited settings start empiric
therapy for PCP on the basis of its clinical case defini-
tion [18]. A number of local guidelines have incorpo-
rated this into their management protocols. Although
this approach may have an acceptable predictive value in
the correct clinical and epidemiological context, inaccu-
rate diagnosis carries a number of important implications,
especially in resource-poor countries. These include incor-
rect assessment for intensive care unit eligibility where
outcomes with PCP are reportedly poor [19] and inappro-
priate timing of initiation of antiretroviral therapy [20].
Over-diagnosis also exposes patients unnecessarily to the
potentially toxic effects of high dose cotrimoxazole [21]
and to the morbidity of delaying treatment for other diag-
noses such as tuberculosis [22]. The consequences of
under-treating PCP because of a misunderstanding of
local prevalence are serious [11], with case fatality rates
approaching 30% [10]. A better understanding of the
regional prevalence of PCP would therefore support
clinical management decisions and may ultimately in-
fluence outcomes.
There are a number of published reviews examining
the prevalence of HIV-associated PCP in developing
countries [17,22,23], but none has focused on the adult
population in sub-Saharan Africa (SSA). We therefore,
plan to conduct a systematic review and meta-analysis
to investigate the burden of PCP among HIV-infected
adults in this region, with the hypothesis that PCP has a
greater contribution to morbidity and mortality than
previously recognised.
Aims and definitions
The primary outcome measures of this systematic review
are the prevalence, mortality and case fatality of PCP in
HIV-infected adults in SSA. We have defined prevalence
as PCP diagnosed among patients with compatible symp-
toms and signs who would normally warrant testing at a
given hospital or clinic. It does not refer to the population
prevalence of disease. Mortality is defined as the pro-
portion of deaths in a study cohort that are due to PCP
(PCP deaths/total deaths), and case fatality as mortality
among confirmed or probable cases (PCP deaths/total
PCP diagnoses).
Secondary outcome measures include an assessment
of the number and quality of studies addressing the pri-
mary research question as well as an analysis of demo-
graphic and characteristics of cases. This includes rates
of co-infection with tuberculosis and other opportunistic
infections. Where possible we also plan to determine the
number of participants colonised with P. jirovecii.Eligibility criteria
Types of participants
Participants in eligible studies must reside in a SSA
country at the time of enrolment and will not be ex-
cluded on the basis of legal migration status. We will
analyse the data from HIV-1-infected or dual HIV-1-/
2-infected adults only. We will include participants from
eligible studies with an age cutoff of 15 years.
Study design and setting
We will not limit eligibility on the basis of study design
and will include autopsy studies, retrospective and pro-
spective clinical studies. Case reports and review articles
will be excluded as will any publication from a paediatric
journal. All studies published before 1995 will be ex-
cluded. This date cutoff was chosen because it roughly
coincides with the introduction of cotrimoxazole pro-
phylaxis in Africa, as well as the development of im-
proved diagnostics for PCP. There will be no restriction
on the clinical setting, allowing studies analysing both
in- and outpatients at any healthcare level to be included
for analysis.
Outcomes
Studies will be included if they provide clear diagnostic
criteria and well-defined study populations (denominator)
with mortality or case fatality data. Our definition of clin-
ical PCP disease requires any one of the following criteria:
1. A clear clinical case definition (based upon the
WHO criteria), including all of the following:– Compatible radiology: bilateral interstitial
infiltrates
– Compatible clinical presentation: acute/subacute,
respiratory distress, hypoxia at rest or
desaturation on minimal exertion
– Response to PCP therapy after failing empiric
antibiotics
– No other explanation for presentation
2. Visualisation of oocysts/trophozoites by any method
from respiratory specimen
3. Positive PCR (any method) with compatible clinical
syndrome responding to PCP therapy
We have defined colonisation with P. jirovecii as a posi-
tive PCR (any method) on symptomatic patients who have
spontaneous recovery without specific PCP therapy.
Methods and design
Search strategy
A broad search strategy has been designed to maximise
sensitivity. This has been developed with the assistance
Table 1 Search strategy










#9 #6 OR #7 OR #8





#15 Aids-related opportunistic infections
#16 #11 OR #12 OR #13 OR #14 OR #15
#17 Acquired immunodeficiency syndrome
#18 Aids serodiagnosis
#19 #17 OR #18
#20 #16 OR #19
#21 Africa





#27 #21 OR #22 OR #23 OR #24 OR #25 OR #26
#28 Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR
Central African Republic OR Chad OR Congo OR Cote d Ivoire OR
Democratic Republic of the Congo OR Djibouti OR Ethiopia OR
Eritrea OR Equatorial Guinea OR Gabon OR Gambia OR Ghana
OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia
OR Malawi OR Mali OR Mauritania OR Mozambique OR Namibia
OR Niger OR Nigeria OR Rwanda OR Senegal OR Sierra Leone OR
Somalia OR South Africa OR Sudan OR Swaziland OR Tanzania
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University of Cape Town. The main search comprises in-
dividual searches using detailed medical subject heading
(MeSH) terms for pneumocystis pneumonia, community-
acquired pneumonia and HIV/AIDS combined with terms
relevant to SSA. We plan to search Medline (accessed via
PubMed), Web of Science (accessed via IST Web of
Knowledge), Africa-Wide: NiPAD and CINAHL (both
accessed via EBSCO Host) databases in an attempt to
identify all relevant articles, irrespective of publication
type, listed from 1995. There will be no language restric-
tion. Table 1 shows an outline of our planned search stra-
tegy. We will complement this process by reviewing
citations of all eligible studies and reviews identified
by the search and search in Google Scholar.
Study selection
All studies retrieved by the searches will be imported
into Refworks online reference management system
(www.refworks.com). The first author will screen titles
and abstracts for location, patient population and gen-
eral correlation with our research objectives. Full ver-
sions of potentially relevant articles will be obtained to
assess eligibility. These will then be independently evalu-
ated for inclusion by two authors. A quality-scoring
guide (described below and shown in Table 2) has been
developed to allow consistent application of inclusion
criteria between authors. Any disagreements on eligibil-
ity will be resolved through discussion and consultation
with the third author who makes the final decision on
selection.
Data extraction
Data will be collected independently by two individual
reviewers from each eligible publication and captured
onto a standardised form. We plan to extract data from
text, tables and figures. Study authors will be contacted
in cases of missing data or unclear eligibility criteria.
The following variables will be captured:
– Study characteristics
OR Togo OR Uganda OR United Republic of Cameroon OR Zaire
OR Zambia OR Zimbabwe
#29 #27 OR #28
#30 #10 AND #20 AND #29○ Year of publication and study period
○ Design, objectives and inclusion criteria
– Study population
○ Country and clinical setting
○ Denominator
▪ Total recruitment/enrolment and attrition rate
▪ Numbers assessed for PCP
○ Characteristics of study participants
▪ CD4 count
▪ Exposure to antiretroviral therapy and PCP
prophylaxis
– Diagnostic methods




○ Co-infections with tuberculosis and other
opportunistic infections
○ CD4 count, age and gender
Table 2 Quality assessment tool
1. Study design (selection score)
a. Prospective clinical studies (any type)
- Consecutive enrolment 2
- Unspecified/random enrolment 1
b. Autopsy studies
- Consecutive enrolment 2
- Unspecified/random enrolment 1
c. Retrospective reviews (including subgroup analysis) 1
d. Review/editorial 0
e. Case report 0
2. Study objectives (selection score)
a. Clear inclusion criteria
- Aim related to PCP prevalence or outcomes 3
- Related to OIs/general morbidity/respiratory disease but
not specific to PCP
2
- Unrelated to clinical PCP prevalence 1
b. Unclear inclusion criteria 1
3. Diagnosisa (quality of outcome ascertainment)
a. Laboratory-confirmed (any specified method/specimen) 2
b. Clinical case definition (consistent with WHO guidelines) 1
c. Not specified 0
4. Denominator
a. Raw data denominator 2
b. Calculated denominator 1
c. No/unclear denominator/investigated < 20% of cohort for
PCP/ exclusion group
0
5. Numerator (PCP numbers)
a. Raw data numerator 2
b. Calculated numerator 1
c. No/unclear numerator (clinical PCP not mentioned/tested) 0
6. Assessment of bias (low, high or unclear risk)
a. Attrition bias
- Amount, nature or handling of incomplete outcome data
b. Selection bias
- Representativeness of the cases/cohort (clear reasons for
and rates of non-inclusion)
aDo not include data from clinical episodes of PCP if no case definition
provided (even if study otherwise qualifies).
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prophylaxis
– PCP deaths
○ Mortality and case fatality
Eligible studies will be categorised according to the
outcome data they provide (that is, prevalence, mortality,
case fatality) and the clinical setting in which the parti-
cipants are assessed. These groups are prespecified asinpatients with respiratory symptoms, unselected inpa-
tients and all outpatients.
Quality assessment and risk of bias
A quality assessment tool (Table 2) has been developed
and will be applied to screened full-text articles in order
to code eligibility decisions and to assess study quality
and agreement between investigators. Our scoring sys-
tem is based on the Newcastle Ottawa Scale and on a
novel scale used in a previously published prevalence re-
view [24]. It scores selection of participants with an em-
phasis on quality of study design; those with consecutive
enrolment and transparency of inclusion criteria achieve
the highest scores. A qualitative score of diagnostic me-
thods for PCP is used to assess eligibility and quality of
outcome ascertainment. There are also ratings for the
quality of denominator and numerator data. Assessment
of bias is built into the quality scoring scale. We plan to
evaluate risk of selection and attrition bias using the
Cochrane guidelines as set out in Review Manager ver-
sion 5.2 (http://ims.cochrane.org/RevMan). This will in-
form the feasibility of and selection of studies for a
pooled analysis. We also plan to conduct an assessment
of the overall strength of evidence obtained from in-
cluded studies. This will take into account the following
factors: allocated quality and risk of bias scores des-
cribed above; the total number of included studies; and
consistency of results across similar clinical settings using
the same diagnostic methods. Any disagreements will be
resolved by discussion and consensus in consultation with
the third author to resolve persistent inconsistencies.
Data synthesis
Prevalence data from individual studies will be combined
by random effects meta-analysis according to the Mantel-
Haenszel method. Heterogeneity will be evaluated using
the χ2-based Q statistic (significant for P <0.1) and the I2
statistic (>50% to be indicative of ‘notable’ heterogeneity
[25]). STATA software version 9.2 (STATA Corporation,
College Station, TX, USA) will be used to perform calcula-
tions and the meta-analysis and to produce the forest
plots using the metan routine. Should standard errors (SE)
not be provided, confidence intervals will be incorporated
into the formula, SE = (upper limit - lower limit)/3.92.
Presenting and reporting of results
We plan to make use of flow diagram to summarise the
study selection process and detail the reasons for ex-
clusion of studies screened as full text. This will follow
the PRISMA guidelines for reporting of systematic re-
views [26]. We will publish our search strategy and
quality-scoring tool as supplementary documents. Pri-
mary outcome measures will be reported in the prespe-
cified categories described above in the ‘Data extraction’
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bles of individual studies as well as in summary tables and
forest plots where appropriate. We plan to report on qual-
ity scores and risk of bias for each eligible study. This may
be tabulated and accompanied by narrative summaries. A
descriptive analysis of the strength of evidence assessment
will be reported.
Discussion
To our knowledge there are no published reports of
studies that have specifically assessed the burden of PCP
in SSA. We plan to address this gap with the systematic
review and meta-analysis outlined in this protocol. Fur-
thermore, there are no validated guidelines for the per-
formance of prevalence reviews. We have developed a
novel quality scoring system to enhance fidelity to inclu-
sion criteria, reduce selection bias among investigators
and to allow for a standardised assessment of the qua-
lity of included studies. This system may potentially
be adapted for use in future prevalence reviews of other
diseases.
The findings of this systematic review will have impli-
cations for the clinical management of HIV-associated
community-acquired pneumonia in SSA. Understanding
the pretest probability of PCP in this setting will help to
rationalise treatment decisions and guide interpretation
of diagnostic tests. This study may also inform local
guidelines and management algorithms in terms of re-
commendations for empiric therapy and referral for fur-
ther investigation. Understanding the contribution of
PCP to mortality in selected populations is important
for resource allocation and motivation for better diag-
nostic tests. Demonstration of a high case fatality may
encourage more aggressive initial management and pos-
sibly earlier referral to intensive care units. Our second-
ary outcome measures will characterise the patients with
PCP in this region and may provide a better understan-
ding of rates of co-infection with other opportunistic
pathogens. Finally, we hope to identify gaps in research
that may form the basis of future studies of various as-
pects of pneumocystis pneumonia in SSA.
Protocol registration
This review protocol has been published in the PROS-
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